Implementation of a stepped anti-inflammatory reliever therapy intervention with budesonide-formoterol 160/4·5 mcg by Turbuhaler versus usual care for adults presenting during exacerbations of obstructive lung disease suggestive of asthma or chronic
This trial was funded by the National Health and Medical Research Council of Australia. The study sponsor was the Woolcock Institute of Medical Research. Budesonide-formoterol was provided by AstraZeneca.
Authors
- Qingbin Li (ORCID: https://orcid.org/0009-0003-7882-1319)
- Pham Ngoc Yen
- Helen Kathryn Reddel (ORCID: https://orcid.org/0000-0002-6695-6350)
- Ngo Quy Chau (ORCID: https://orcid.org/0000-0002-6787-2757)
- Guy B. Marks (ORCID: https://orcid.org/0000-0002-8976-8053)
- Thu Anh Nguyen (ORCID: https://orcid.org/0000-0002-2089-2902)
- Greg J. Fox (ORCID: https://orcid.org/0000-0002-4085-1411)
- Giap Van Vu (ORCID: https://orcid.org/0000-0002-8821-6353)
- Stephen Jan (ORCID: https://orcid.org/0000-0003-2839-1405)
- Joel Negin (ORCID: https://orcid.org/0000-0002-2016-311X)
- Erick Wan-Chun Huang (ORCID: https://orcid.org/0000-0002-3781-103X)
Institutions
- New South Wales Department of Health (AU)
- Burnet Institute (AU)
- Pham Ngoc Thach University of Medicine (VN)
- Hanoi Medical University (VN)
- Royal Prince Alfred Hospital (AU)
- Woolcock Institute of Medical Research (AU)
- The George Institute for Global Health (AU)
- Khanh Hoa General Hospital (VN)
- Bạch Mai Hospital (VN)
- Macquarie University (AU)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103642
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00